---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-008698"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2026-01-30T23:59:59+00:00"
generated_at: "2026-05-16T05:54:30.824373+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Madrigal gains full control over Rezdiffra patent term extensions from Roche

## Summary
- Madrigal gets exclusive right to manage all patent term extensions for Rezdiffra, including Roche-owned and joint patents.
- Royalty reduction on Rezdiffra net sales is deferred until expiration of certain patent term extensions that have been or could be filed.
- Amendment modifies the 2008 Research, Development, and Commercialization Agreement with Roche.
- Madrigal also obtains full rights over joint patent rights and know-how without consent or accounting to Roche.

## SEC filing metadata
- accession: 0001104659-26-008698
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2026-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000110465926008698/0001104659-26-008698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000110465926008698/tm264540d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-008698
- JSON: https://secwatch.observer/filing/0001104659-26-008698.json
- Plain text: https://secwatch.observer/filing/0001104659-26-008698.txt

## Key facts
- Material Agreements
  MADRIGAL PHARMACEUTICALS, INC. amended First Amendment to the Research, Development, and Commercialization Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) (effective 2026-01-29).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”)
  - Effective: 2026-01-29
  source text: On January 29, 2026 (the “Effective Date”), Madrigal Pharmaceuticals, Inc. (the “Company”), F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) entered into the First Amendment (the “Amendment”) to the Research, Development, and Commercialization Agreement dated as of December 18, 2008 between the Company and Roche.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157601/000110465926008698/0001104659-26-008698-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.